Navigation Links
Discovery could help to develop drugs for organ transplant and cancer patients
Date:4/13/2012

MAYWOOD, Ill. -- Loyola researchers are reporting surprising findings about a molecule that helps ramp up the immune system in some cases and suppress it in others.

The finding eventually could lead to new drugs to regulate the immune system by, for example, revving it up to attack tumor cells or tamping it down to prevent the rejection of transplanted organs.

The study is published online ahead of print in the Journal of Immunology. Senior author is Makio Iwashima, PhD, an associate professor in the Department of Microbiology & Immunology of Loyola University Chicago Stritch School of Medicine. Co-authors are Robert Love, MD, a professor in the Departments of Thoracic & Cardiovascular Surgery and Microbiology & Immunology and one of the world's leading lung transplant surgeons, and first author Mariko Takami, PhD, of the Department of Microbiology & Immunology.

The immune system relies on a balancing act between two types of cells. Effector cells attack tumor cells and cells infected by viruses or bacteria. Regulatory cells suppress the immune system so that it does not attack healthy tissue. If effector cells are too active, an individual can suffer autoimmune disorders such as lupus, Type 1 diabetes and multiple sclerosis. But if regulatory cells are too active, the immune system will not be aggressive enough to protect the individual from germs and cancer.

The study involved an immune system molecule called transforming growth factor beta (TGF-β). TGF-β is known to be a powerful regulator of the immune response -- generally suppressing the strength of the response. In this study, however, Loyola researchers demonstrated that TGF-β can amplify the immune response and result in a more effective targeted response under specific conditions.

"TGF-β is a double-edged sword," Iwashima said. "It augments immune system reactions but does not determine what direction they will take. Depending on conditions, these reactions can either activate or suppress the immune system."

The study involved mouse cells grown ex vivo in laboratory dishes. The next steps will be to study TGF-β in human cells and in animal models. Understanding the dual role of TGF-β could help in the development of drugs to either activate or suppress the immune system, as needed, Iwashima said.


'/>"/>

Contact: Jim Ritter
jritter@lumc.edu
708-216-2445
Loyola University Health System
Source:Eurekalert

Related medicine news :

1. Washingtons Life Sciences Discovery Fund awards commercialization grants
2. Scientist awarded $1 million grant to develop tools for hepatitis C treatment discovery
3. New discovery of proteins involved in positioning muscular nuclei
4. Cell signaling discovery provides new hope for blood disorders
5. Gene mutation discovery sparks hope for effective endometriosis screening
6. Discovery predicts patient sensitivity to important drug target in deadly brain cancer
7. Discovery of new vaccine approach for treatment of cancer
8. Zebrafish may help speed drug discovery
9. Unexpected discovery opens up new opportunities for targeting cancer
10. Journal names discovery that HIV treatment can prevent spread breakthrough of the year
11. Salk discovery may lead to safer treatments for asthma, allergies and arthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... ... December 08, 2016 , ... ... Medication Therapy Management (MTM), adherence, and other pharmacist-delivered patient care services, has announced ... counsel and Eric Hoessel to vice president of sales. , Litsinger joined ...
(Date:12/8/2016)... ... December 08, 2016 , ... Premier Fitness Camp (PFC) ... , the ultimate weight loss and wellness program, at their world headquarters of Omni ... provide immediate and long-term results to anyone seeking weight loss, personal development, a healthy ...
(Date:12/8/2016)... ... December 08, 2016 , ... STATEN ... been recognized for adherence to the highest standards of trauma, maternity, cancer and ... the center's president and CEO, Dr. Daniel Messina. , Among the recognitions, the ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... Care Act. Dr. Botelho advocates for the mass media launching of story movements ... ongoing opportunities to share their unfortunate experiences; such a movement can generate the ...
(Date:12/8/2016)... ... December 08, 2016 , ... The Dan Carlisle Agency, ... Jefferson County, is announcing the launch of a charity drive to raise support ... homeless women and children in Birmingham has grown steadily since the 1980’s, and ...
Breaking Medicine News(10 mins):
(Date:12/9/2016)... Research and Markets has announced the addition of the ... ... forecasts the global optical transceiver market to grow at a CAGR ... covers the present scenario and the growth prospects of the global ... report considers the revenue generated from the shipment of optical transceivers ...
(Date:12/9/2016)... Dec. 9, 2016  RxWiki Inc., a digital health ... marketing strategies of thousands of pharmacies through its Digital ... Austin Inno,s "50 on Fire" Award in the ... pleased to accept the award as one of Austin,s ... Executive Officer at RxWiki. "Our platform gives independent retail ...
(Date:12/8/2016)... 2016 IRIDEX Corporation (NASDAQ: IRIX ) ... of common stock, $0.01 par value (the "Offering" with such ...  The final terms of the Offering will depend on market ... can be no assurance as to whether or when the ... the net proceeds it will receive from this offering for ...
Breaking Medicine Technology: